NY-ROBOSENSE
13.2.2020 15:02:10 CET | Business Wire | Press release
RoboSense’s automotive MEMS LiDAR“RS-LiDAR-M1” has been named a finalist in transportation &Logistics category for the 2020 Edison Awards. The Edison Awards, named after Thomas Alva Edison, recognizes and honors the world’s best innovations and innovators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005321/en/
The Edison Awards is one of the world's prestigious awards that symbolize the persistence and excellence in innovation and honors the most innovative products and business leaders in the world. It is Established in 1987 and named after inventor Thomas Alva Edison and sometimes referred to as “The Oscars of Innovation”. All the winners were chosen as the "best of the best" by the globe review panel consist of 3,000 senior business executives and academics.
The RoboSense RS-LiDAR-M1 is the world’s first and smallest MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 meets every automotive-grade requirement, including intelligence, low cost, stability, simplified structure and small size, vehicle body design friendliness, and algorithm processed semantic-level perception output results.
As the game-changing product in the autonomous driving field, the RS-LiDAR-M1 hard-ware only version is currently available for customers, with a retail price of $1898. The smart sensor version is currently available for key customers who have purchased the solid-state LiDAR A-C Sample Kit. At CES 2020, the RoboSense RS-LiDAR-M1 also demonstrated that it is the world’s first and only Smart LiDAR capable of real road tests on open roads.
RoboSense Smart LiDAR Sensor RS-LiDAR-M1 installed on a vehicle
“Winning of the 2020 Edison Award is a recognition of RoboSense’s innovation technology towards the future mobility and its benefits for the human driving safety”, Dr. Leilei Shinohara, RoboSense Co-partner and Vice President said, “with the achievement of the IATF 16949 Certification, RoboSense is qualified to supply to automotive customers. We are confident that the RS-LiDAR-M1 is the best choice for the mass production of autonomous driving. We continuously focus on the validation and verification of performance and quality of RS-LiDAR-M1 as an automotive-grade product”.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
Attracted an all-star team from leading corporations and institutions around the world，there are 500+ employees in 6 global locations-Shenzhen, Beijing, Shanghai, Suzhou, Stuttgart, and Silicon Valley to support RoboSense's fast-growing in innovation and development. Until 2019, RoboSense owns more than 500 patents globally. For more information, see the website:
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005321/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom